Compare LCFY & XAIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | LCFY | XAIR |
|---|---|---|
| Founded | 2009 | 2011 |
| Country | Australia | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.2M | 10.5M |
| IPO Year | 2022 | N/A |
| Metric | LCFY | XAIR |
|---|---|---|
| Price | $3.72 | $1.01 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $11.00 |
| AVG Volume (30 Days) | 18.3K | ★ 115.6K |
| Earning Date | 03-13-2026 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $2,099,713.00 | ★ $5,802,000.00 |
| Revenue This Year | N/A | $128.45 |
| Revenue Next Year | N/A | $153.25 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 147.74 |
| 52 Week Low | $2.51 | $1.00 |
| 52 Week High | $13.98 | $11.20 |
| Indicator | LCFY | XAIR |
|---|---|---|
| Relative Strength Index (RSI) | 44.79 | 28.59 |
| Support Level | $3.70 | $1.10 |
| Resistance Level | $4.03 | $1.31 |
| Average True Range (ATR) | 0.24 | 0.10 |
| MACD | 0.10 | 0.01 |
| Stochastic Oscillator | 61.32 | 2.63 |
Locafy Ltd is focused on commercializing its Software as a Service (SaaS) online publishing technology platform. Its platform enables the ability to publish almost any type of content to almost any device that uses a web browser to display web content. The firm has two operating segments: Publishing and SEO agency. Under the Publishing segment are products and services that the Company offers that are related to digital properties (i.e. mastheads) that it owns e.g. business data published on Hotfrog, advertising placed on AussieWeb, articles published on scoop.com.au. In contrast, under the SEO Agency segment are products and services that are applied to digital properties that are owned and operated by third parties. It derives a majority of its revenue in North America from SEO Agency.
Beyond Air Inc is a commercial-stage medical device and biopharmaceutical company that develops a Nitric Oxide (NO) Generator and Delivery System that uses NO generated from ambient air and delivers precise amounts of NO to the lungs for the potential treatment of respiratory and other diseases. The firm is applying its therapeutic expertise to develop treatments for pulmonary hypertension, in addition to treatments for lower respiratory tract infections.